Best Selank Source: Judged Against a Release Specification

Best selank source pages almost always run in the wrong order. They name a winner, then reverse-engineer reasons that fit it, which is unfalsifiable and useless to anyone deciding what to buy. So the weighting comes first here and the scoring afterwards. Disagree with the weighting and you can re-run the arithmetic with your own numbers, which is the point.

The benchmark is borrowed rather than invented. A licensed drug product is released against a specification: a defined set of tests with defined acceptance criteria, all of which have to pass before a batch leaves the building. Selank has no such route in the United States, for reasons set out below. So the question is which source comes closest to a release specification voluntarily, and how far short the closest one falls.

We earn a commission if you buy through the supplier we link, which our affiliate disclosure sets out. It scores 95 out of 100 below on its current batch, and the 5 points it drops are itemised.

Testing scope carries 30 points, the largest single block, because it is the criterion FDA's own concern identifies. On its page covering bulk substances that may present significant safety risks, FDA writes that compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. Aggregation and contamination are addressed by bacterial endotoxin testing and a sterility or microbial screen. Nothing else on this list measures them.

Traceability carries 20 points. A certificate that names a lot you can match against your vial is the difference between evidence and decoration. Without it, every other analytical figure describes a batch you have no reason to believe you received. It scores second only because it is worthless on its own: a lot number attached to a narrow test panel still leaves the main risk unmeasured.

Identity and purity carry 15 points together. Identity means mass spectrometry against the expected monoisotopic mass of 751.43 daltons, consistent with the formula C33H57N11O9 and molecular weight 751.9 recorded on the PubChem entry. Purity means HPLC with the chromatogram reproduced, not a percentage in a graphic. This block is weighted lower than people expect because it is the part of the market that is already largely solved: most credible sellers publish it, so it discriminates less.

Supply chain control carries 12 points: domestic stock, a published dispatch cutoff, and no customs step. Recourse carries another 12: card payment, a named business, and a written returns policy. Price transparency carries 6, meaning a published price with the discount arithmetic visible rather than a quote on request. Claims discipline carries the last 5: a source that publishes human dosing guidance alongside a research-use label has contradicted itself on one page, and that tells you how it treats every other statement it makes.

That is 100 points, weighted so that no amount of good behaviour on price, speed or design compensates for an unmeasured contamination risk. If your priorities differ, move the numbers; the evidence underneath does not change.

One decision needs explaining, because it makes this page shorter than its competitors. We are not publishing a scored table of named vendors: we have read one supplier's certificates end to end, and inventing scores for six others would be the failure described at the top of this page.

So the ranking is by source type first, which is where the large differences actually are, followed by a specific score for the one source we have documents for. Source types are not a dodge here: the gap between a domestic supplier with a lot-specific certificate and a grey-market reseller is far larger than the gap between any two domestic suppliers.

A compounding pharmacy is excluded from the ranking rather than placed last, because it is not a source at all. FDA's 503A bulk substances page, content current as of 14 May 2026, sets a three-part test: a USP or NF monograph, or component status in an FDA-approved drug product, or presence on the 503A bulks list. Selank fails all three. Any pharmacy supplying it is operating outside that framework, which disqualifies it on the criterion that would otherwise be its whole advantage.

A domestic research supplier publishing a lot-specific certificate takes first, and the margin comes almost entirely from traceability and recourse. It is the only source type where you can read the analytical data before paying, match it to the vial afterwards, and dispute the charge if the two disagree.

A domestic supplier without a published certificate takes second, a long way back. Domestic stock, card payment and a returns policy are real advantages attached to a product you know nothing about analytically. Purity on request, after payment, is a different offer from purity you can read now.

An overseas bulk marketplace takes third. Per-milligram cost is genuinely lower, the only category where that is true. Everything else moves against you: certificates describing a batch rather than your batch, weeks of uncontrolled transit, payment by transfer with no dispute route, and an unapproved drug that may be refused entry.

A nootropic retailer selling a finished nasal spray takes fourth: the most convenient purchase on the list, and the one with the most undocumented manufacturing steps behind it. A certificate for the raw peptide, where one exists, describes the powder before a party that is not a drug manufacturer dissolved, formulated, filled and sealed it.

A grey-market reseller takes last. Repackaging severs the connection between whatever testing was done and the vial you receive, and introduces exactly the handling that produces the aggregation FDA named. Payments here are final by design. The one thing it reliably supplies is a lower price with nothing behind it.

Ascension Peptides is the supplier this page links, and here is the arithmetic rather than a verdict.

Testing scope: 30 of 30 on the current batch, 0 of 30 on the previous one. The certificate for batch 29-05260628, certified 2 June 2026 by Kovera Labs, carries a bacterial endotoxin analysis by kinetic chromogenic LAL to USP Chapter 85 reporting under 0.20 EU/mL against a 0.5 EU/mL limit, a rapid sterility screen returning no growth, and an ICP-MS heavy metals panel, at 99.371 percent purity and 11.86 mg net content. The February certificate for lot 29-01260229, issued by MZ Biolabs in Tucson, carries none of those tests. The points belong to the document, not to the shop, so score the batch you are actually shipped.

Traceability: 20 of 20. The certificate names a specific lot, and the lot is printed on the vial, so the match is checkable on arrival. That is the criterion most competitors fail, and it is the reason this supplier ranks where it does despite the block above.

Identity and purity: 15 of 15, on both documents. The February lot reports 99.32 percent by HPLC-UV with the chromatogram reproduced, showing the main peak at 7.13 minutes and one minor peak at 6.36 minutes accounting for 0.68 percent, and identity by mass spectrometry against an expected monoisotopic mass of 751.43 daltons at a measured 751.47. The June batch reports 99.371 percent with identity by LC-MS. There is also a quantification most sellers do not attempt: 12.29 mg per vial against a 10 mg label in February and 11.86 mg in June, published rather than rounded to the label figure. Those figures are batch specific and are not a promise about the next one.

Supply chain control: 12 of 12. Stock is held domestically with a published same-day dispatch cutoff of 2pm CST, which removes the customs and transit exposure that dominates the overseas category.

Recourse: 12 of 12. Card payment through a named business with a published returns policy, which preserves a dispute route. Price transparency: 6 of 6. Selank 10 mg is listed at $47.50, reduced from $60.00, and $23.75 with the code PEPTIDEDECK, which is $2.38 per milligram. Quantity purchases of three, five or ten take 3, 5 or 10 percent off list; nothing published says the code stacks with those tiers, so they read as alternatives. Free shipping starts at $250.

Claims discipline: 0 of 5. This one is a judgement call and we are marking it down rather than up. The product is correctly sold as research material not for human consumption, which is right. But a research-use position sits awkwardly beside consumer-facing marketing, and we would rather flag the tension than score it as a clean pass. Total: 95 of 100 on batch 29-05260628.

It is worth being clear about what those 30 points do and do not settle. The sterility result is a rapid 2 day screen, and the report says in its own methodology note that full USP Chapter 71 testing may be required for regulatory compliance, so it is a screen rather than a guarantee. The endotoxin figure is measured across a 2.0 mL dilution volume, which is under 0.40 EU in the vial and stays inside the 0.5 EU/mL limit at any reconstitution volume of 1 mL or more.

It is also worth being clear that the points came from a batch rather than from a policy. The vendor's Semax listing shows the same February-to-June change, on batch 30-05260628 certified 15 June 2026, two weeks after the Selank batch. Both June documents are from Kovera Labs and both February ones from MZ Biolabs, so the panel moved with the laboratory and the date across the catalogue.

The practical trap follows from that. On either listing the clickable link can still be the older, thinner February PDF while the fuller June document sits beside it as an image, which is exactly how a reader concludes that one product is tested and the other is not. Read every certificate on the product page, not only the one that is a link.

That turns into a specific, answerable question rather than a complaint. Ask which batch is being shipped to you and ask for that batch's certificate. A batch tested to the June panel scores the full 95. A batch still on the February document scores 65 on the same weighting, and that gap is the whole reason to ask.

The table sets the weighting against the score, so the arithmetic is visible rather than asserted. The rightmost column is the evidence each rests on.

One caution about reading a 95. It is not 95 percent as good as a pharmacy product. Prescriber oversight and a recall path that reaches your address are not criteria on this list at all, because no source in this channel offers them. The scale measures the best available version of a channel structurally missing its top half.

Asked which Selank source to use, the answer is a domestic supplier publishing a lot-specific certificate, and the follow-up is whether the batch you are shipped is covered for endotoxins. On the June batch it is. On the February one it is not, so the decision is to confirm the batch before buying rather than to trust the shop.

What is not defensible is buying on price or site design. The difference between sources here is not a few cents per milligram. It is whether anything you were shown describes the vial that arrives.

For the criteria applied to listings rather than sources, our guide to reading a Selank listing covers the fields a pharmacy label would carry. Our BPC-157 source ranking shows the same weighting on an adjacent peptide, and our wider guide to trusted peptide sourcing covers the vendor-level checks.